Joseph Schwartz
Stock Analyst at Leerink Partners
(4.13)
# 478
Out of 5,135 analysts
157
Total ratings
35.51%
Success rate
21.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $80 → $70 | $20.45 | +242.30% | 7 | Dec 30, 2025 | |
| FOLD Amicus Therapeutics | Downgrades: Market Perform | $17 → $15 | $14.34 | +1.15% | 13 | Dec 29, 2025 | |
| SPRB Spruce Biosciences | Upgrades: Outperform | $160 | $52.75 | +203.32% | 7 | Dec 3, 2025 | |
| DSGN Design Therapeutics | Upgrades: Outperform | $7 → $14 | $10.05 | +39.37% | 5 | Dec 3, 2025 | |
| IFRX InflaRx | Downgrades: Market Perform | $5 → $2 | $0.87 | +129.17% | 5 | Dec 3, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | $82 → $60 | $61.83 | -2.96% | 11 | Dec 3, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Market Perform | $15 → $16 | $14.30 | +11.89% | 7 | Dec 3, 2025 | |
| QURE uniQure | Maintains: Outperform | $68 → $60 | $23.45 | +155.86% | 3 | Nov 10, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Outperform | $115 | $55.35 | +107.77% | 1 | Nov 10, 2025 | |
| RNA Avidity Biosciences | Downgrades: Market Perform | $65 → $72 | $72.83 | -1.14% | 4 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $43.46 | +102.49% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $12 → $15 | $18.40 | -18.48% | 14 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $15.44 | +29.53% | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $115 | $151.13 | -23.91% | 4 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $12 | $10.92 | +9.89% | 4 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $45.16 | -38.00% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $40 | $27.85 | +43.63% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.05 | - | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $5.93 | +102.36% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $0.43 | +1,751.85% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $68.97 | -30.40% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $26.78 | -32.79% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $82.21 | -58.64% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $226.47 | -28.03% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.17 | +361.89% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $6.53 | +405.36% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $64 → $52 | $10.31 | +404.36% | 5 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $30.06 | -0.20% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $82.88 | -63.80% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $1.50 | +700.00% | 2 | Sep 26, 2017 |
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $80 → $70
Current: $20.45
Upside: +242.30%
Amicus Therapeutics
Dec 29, 2025
Downgrades: Market Perform
Price Target: $17 → $15
Current: $14.34
Upside: +1.15%
Spruce Biosciences
Dec 3, 2025
Upgrades: Outperform
Price Target: $160
Current: $52.75
Upside: +203.32%
Design Therapeutics
Dec 3, 2025
Upgrades: Outperform
Price Target: $7 → $14
Current: $10.05
Upside: +39.37%
InflaRx
Dec 3, 2025
Downgrades: Market Perform
Price Target: $5 → $2
Current: $0.87
Upside: +129.17%
BioMarin Pharmaceutical
Dec 3, 2025
Downgrades: Market Perform
Price Target: $82 → $60
Current: $61.83
Upside: -2.96%
Aurinia Pharmaceuticals
Dec 3, 2025
Downgrades: Market Perform
Price Target: $15 → $16
Current: $14.30
Upside: +11.89%
uniQure
Nov 10, 2025
Maintains: Outperform
Price Target: $68 → $60
Current: $23.45
Upside: +155.86%
Monopar Therapeutics
Nov 10, 2025
Initiates: Outperform
Price Target: $115
Current: $55.35
Upside: +107.77%
Avidity Biosciences
Oct 27, 2025
Downgrades: Market Perform
Price Target: $65 → $72
Current: $72.83
Upside: -1.14%
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $43.46
Upside: +102.49%
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $18.40
Upside: -18.48%
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $15.44
Upside: +29.53%
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $151.13
Upside: -23.91%
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $10.92
Upside: +9.89%
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $45.16
Upside: -38.00%
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $27.85
Upside: +43.63%
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.05
Upside: -
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $5.93
Upside: +102.36%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $0.43
Upside: +1,751.85%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $68.97
Upside: -30.40%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $26.78
Upside: -32.79%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $82.21
Upside: -58.64%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $226.47
Upside: -28.03%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.17
Upside: +361.89%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $6.53
Upside: +405.36%
Aug 5, 2022
Downgrades: Market Perform
Price Target: $64 → $52
Current: $10.31
Upside: +404.36%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $30.06
Upside: -0.20%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $82.88
Upside: -63.80%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $1.50
Upside: +700.00%